Objective This study aims to investigate the safety and feasibility of early oral feeding in patients with gastric cancer after gastrectomy. Methods A total of 135 patients with gastric cancer who ...

5 Reproductive Medicine Center, The First Hospital of Lanzhou University, Lanzhou, Gansu, China Gastric cancer, a prevalent malignancy globally, is influenced by various factors. The imbalance in the ...

A total of 474 participants were randomly assigned to the durvalumab group, and 474 to the placebo group (median follow-up, 31.5 months; interquartile range, 26.7 to 36.6). Two-year event-free ...

NEW YORK – Survival results from the Phase III DESTINY-Gastric04 trial confirmed that AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Enhertu (trastuzumab deruxtecan; T-DXd) should be the ...

Background: Gastric cancer remains a significant global health burden. This study aims to provide a comprehensive analysis of gastric cancer incidence and mortality trends, with a focus on sex, ...

The ACS estimates that the U.S. will see about 30,300 new cases of gastric cancer in 2025, and about 10,780 deaths from this type of cancer (6,400 men and 4,380 women).

Among patients with advanced head and neck squamous cell carcinoma (HNSCC), the combination of evorpacept and Keytruda (pembrolizumab) with or without chemotherapy failed to meet the primary endpoints ...

More information: Durgadevi Ravillah et al, LincPRKD: A Long Intergenic Noncoding RNA Activated in Gastric Cancer, Gastro Hep Advances (2025). DOI: 10.1016/j.gastha.2025.100618 ...

RNA molecule identified as possible driver of gastric cancer With further testing, discovery may offer new target for early detection and treatment Date: March 13, 2025 Source: Case Western ...

Eradicationof Helicobacter pylori (H pylori) significantly lowered adult patients’ risk for gastric cancer, according to results of a systematic review and meta-analysis published in Gastroenterology.

AstraZeneca and Daiichi Sankyo continue to rack up wins for their lead antibody-drug conjugate Enhertu, with a Phase III readout on Monday pointing to the drug’s strong potential in gastric cancer, ...

Gastric cancer (GC) is one of the most common cancers in the world and the leading cause of cancer-related death in China. At present, the intervention measures for GC are limited. Therefore, it is ...